Leading experts in the CLL landscape discuss the latest treatment options for patients and answer questions from the CURE audience.
Related Content:
Knowledge Isn’t Enough When Action Costs Too Much
What Does Minimal Residual Disease Mean?
Preoperative Breast MRI Did Not Improve Outcomes in Early-Stage Breast Cancer
Enhertu/Perjeta Combo Enhances Quality of in HER2+ Advanced Breast Cancer
